Ivermectin MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy End UseBy Distribution ChannelBy Product Form

Ivermectin is a macrocyclic lactone antiparasitic compound formulated as injections, oral solutions, tablets, pour-on liquids and premix powders to treat and prevent worm, mite and insect infestations in cattle, sheep, pigs, poultry and companion animals, and as an approved medicine for several human parasitic conditions including onchocerciasis, scabies and strongyloidiasis. Buyers span commercial livestock operations, veterinary hospitals and clinics, agrovet and retail pharmacy chains, animal health distributors, and human pharmaceutical wholesalers and public health procurement bodies. Formulations are supplied both as the active pharmaceutical ingredient to downstream manufacturers and as finished, ready-to-administer products sold directly to end users.

The global ivermectin market stood at USD 1.65 billion in 2025. A forecast-period rate of 7.03% takes it to USD 3.03 billion by 2034, and the study reports every year in between, passing USD 1.2 billion in 2020, USD 1.55 billion in 2024, USD 1.76 billion in 2026 and USD 2.31 billion in 2030.

On the type axis, growth rates run from 6.15% for Injection up to 8.26% for Powder. Injection carries the volume: USD 0.762 billion and 46.18% of revenue in 2025, USD 1.303 billion and 43% in 2034. The lines gaining share are Powder. Injection and Others lose share without losing revenue.

Cut by application, the largest line is Cow: 37.98% of 2025 revenue, worth USD 0.627 billion, and 35% at USD 1.061 billion by 2034. Poultry grows faster at 9.68% against 6.02%, moving from 19.99% of revenue to 25.01% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views rather than components.

Geographically, 33.4% of 2025 revenue sits in Asia Pacific (USD 0.551 billion rising to USD 1.091 billion) ahead of North America at 22.2% and USD 0.366 billion. Middle East and Africa is smallest, at 10.7%. Asia Pacific, Latin America and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.

Coverage extends to five regions, three type lines and five segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• The global ivermectin market moves from USD 1.2 billion in 2020 to USD 1.65 billion in 2025 and USD 3.03 billion by 2034, the forecast period compounding at 7.03% a year.
• The largest line by type is Injection, worth USD 0.762 billion and 46.18% of revenue in 2025, rising to USD 1.303 billion and 43% by 2034.
• Fastest growth on the type axis belongs to Powder: 8.26% a year, USD 0.492 billion to USD 1 billion, and a share moving from 29.82% to 33%.
• Against a base case of USD 3.03 billion in 2034, the study also reports a bear case at USD 2.66 billion and a bull case at USD 3.44 billion, with the assumptions behind each set out separately.
• Asia Pacific holds 33.4% of global revenue in 2025 at USD 0.551 billion, the largest of the five regions tracked, and reaches USD 1.091 billion by 2034.
• Within Asia Pacific, China is the worked country example, at USD 0.187 billion in 2025; 33.9% of regional revenue in the base year, and USD 0.36 billion by 2034.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Three movements define the forecast period in the global ivermectin market: how the type mix changes, where regional weight shifts, and the rate at which the total compounds.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; the question is which takes the larger part of the growth.

The type mix tilts toward Powder. Powder grows at 8.26% across 2026-2034 against 6.15% for Injection, the widest spread on the type axis. Shares follow: 29.82% to 33% for Powder, 46.18% to 43% for Injection. Revenue rises on both sides; USD 0.492 billion to USD 1 billion and USD 0.762 billion to USD 1.303 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Asia Pacific, Latin America and Middle East and Africa gain regional share. Asia Pacific moves from 33.4% of revenue in 2025 to 36% in 2034, worth USD 0.551 billion rising to USD 1.091 billion; Latin America moves from 16.1% of revenue in 2025 to 18% in 2034, worth USD 0.266 billion rising to USD 0.545 billion; Middle East and Africa moves from 10.7% of revenue in 2025 to 12% in 2034, worth USD 0.177 billion rising to USD 0.364 billion. The remaining regions grow in absolute terms while giving up share: North America at 22.2% moving to 19%, Europe at 17.6% moving to 15%. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

A continuation, not an inflection. Fifteen years of revenue run USD 1.2 billion in 2020, USD 1.55 billion in 2024, USD 1.65 billion in 2025, USD 1.76 billion in 2026, USD 2.31 billion in 2030 and USD 3.03 billion in 2034. The forecast rate of 7.03% sits against 6.58% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

Powder adds the most incremental growth

Three sources account for the growth to 2034: 7.03% compounding across the base, share moving toward the faster type lines, and above-market expansion in the leading regions.

The bear case and what drives it

What the bull case turns on

One type line carries the market

22.2% of the global ivermectin market sits in North America in 2025, worth USD 0.366 billion with USD 0.576 billion projected for 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Its share moves to 19% by 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Injection leads here as it does globally, at 46.18% of 2025 revenue, and Powder again grows fastest at 8.26%. Per-axis and per-country detail for North America sits in the full report.

68% of North America's base-year revenue comes from the United States; USD 0.249 billion, rising to USD 0.374 billion by 2034. At 68% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. The region itself runs USD 0.366 billion to USD 0.576 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in the United States follows the type mix reported at global level: Injection is the largest line at 46.18% of 2025 revenue, moving to 43% by 2034, while Powder grows fastest at 8.26% and takes its share from 29.82% to 33%. Since 68% of North America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. The United States carries its own type breakdown in the full report.

In the United States, ivermectin intended for human use is regulated by the Food and Drug Administration as a prescription drug, requiring approval through a New Drug Application before marketing and adherence to FDA labeling rules covering indications, dosage, and warnings on the prescribing information. Formulations intended for animal use fall under the FDA's Center for Veterinary Medicine, which requires a New Animal Drug Application demonstrating safety and effectiveness for the target species. Manufacturers of either form must operate under current Good Manufacturing Practice requirements, and any promotional claims are constrained to the approved labeling, with off-label use permitted only under a licensed prescriber's judgment rather than manufacturer promotion.

The suppliers tracked in this study (Hero Pharmaceutical, MERCK, HuBei YuanCheng SaiChuang, ENN, LAND, Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health, Virbac, Ceva Sante Animale, Huvepharma, Norbrook Laboratories and Cipla Limited) compete in the United States across the type lines above. Two different problems sit on the same axis: holding Injection at 46.18% of 2025 revenue, and taking Powder while it grows at 8.26%. The full report covers country-level positioning and shares company by company; this summary does not.

Canada is sized at USD 0.088 billion in 2025, rising to USD 0.132 billion by 2034; 5.3% of global revenue and 24% of North America. It is reported separately from the United States across every segmentation axis in the full report.

In Europe, 17.6% of global revenue puts 2025 at USD 0.29 billion and reaches USD 0.455 billion by 2034. Among the five regions it ranks third by revenue in both years.

By 2034 the share stands at 15%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.

Injection leads here as it does globally, at 46.18% of 2025 revenue, and Powder again grows fastest at 8.26%. Europe is reported axis by axis and country by country in the full study.

30% of Europe's base-year revenue comes from Germany; USD 0.087 billion, rising to USD 0.132 billion by 2034. Its 30% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Set against USD 0.29 billion and USD 0.455 billion for the region, it is why this market rather than a smaller one is the one reported in full.

The type pattern in Germany is the global one: 46.18% of 2025 revenue in Injection, 43% by 2034, against 8.26% growth in Powder taking it from 29.82% to 33%. Since 30% of Europe's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-type revenue for Germany appears on its own in the full report.

In Germany, ivermectin for human use is governed by the national medicines framework administered by the Bundesinstitut für Arzneimittel und Medizinprodukte, operating alongside the European Medicines Agency where a centralized or mutual-recognition procedure applies, and any supplier must secure a marketing authorization before sale, accompanied by an approved Summary of Product Characteristics and patient information leaflet in German. Veterinary ivermectin formulations fall under the European Union's Veterinary Medicinal Products framework, which sets its own authorization, pharmacovigilance, and residue-monitoring obligations distinct from the human medicines route. Across both routes, manufacturing sites must conform to Good Manufacturing Practice standards and are subject to periodic inspection by the responsible national authority.

Hero Pharmaceutical, MERCK, HuBei YuanCheng SaiChuang, ENN, LAND, Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health, Virbac, Ceva Sante Animale, Huvepharma, Norbrook Laboratories and Cipla Limited are the suppliers covered in Germany. The commercially relevant division is 46.18% of 2025 revenue in Injection, where the volume is, against 8.26% growth in Powder, where share moves.

France is sized at USD 0.07 billion in 2025, rising to USD 0.105 billion by 2034; 4.2% of global revenue and 24.1% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

The United Kingdom is sized at USD 0.058 billion in 2025, rising to USD 0.086 billion by 2034; 3.5% of global revenue and 20% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

33.4% of the global ivermectin market sits in Asia Pacific in 2025, worth USD 0.551 billion and reaches USD 1.091 billion by 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

Share climbs to 36% by 2034, on growth above the market's own 7.03%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the type split tracks the global one; 46.18% of 2025 revenue in Injection, fastest growth of 8.26% in Powder. The full report breaks Asia Pacific out along every axis and by country.

The largest single market in Asia Pacific is China, at USD 0.187 billion in 2025 and USD 0.36 billion in 2034. Its 33.9% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. The region itself runs USD 0.551 billion to USD 1.091 billion over the same period, and this is the market carrying the country-level detail in the full report.

The type pattern in China is the global one: 46.18% of 2025 revenue in Injection, 43% by 2034, against 8.26% growth in Powder taking it from 29.82% to 33%. Since 33.9% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. China carries its own type breakdown in the full report.

In China, ivermectin intended for human therapeutic use is regulated by the National Medical Products Administration, which requires a drug registration certificate confirming quality, safety, and efficacy before a product may be marketed, together with compliance with national Good Manufacturing Practice standards and approved Chinese-language labeling and package insert content. Veterinary ivermectin products fall instead under the veterinary drug approval framework administered through the Ministry of Agriculture and Rural Affairs, which issues a separate veterinary drug registration and sets its own manufacturing and labeling conformity requirements. Suppliers operating across both the human and animal health segments must therefore maintain two distinct regulatory dossiers rather than a single unified approval.

Competition in China runs between the suppliers this study tracks: Hero Pharmaceutical, MERCK, HuBei YuanCheng SaiChuang, ENN, LAND, Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health, Virbac, Ceva Sante Animale, Huvepharma, Norbrook Laboratories and Cipla Limited. The commercially relevant division is 46.18% of 2025 revenue in Injection, where the volume is, against 8.26% growth in Powder, where share moves.

8.7% of global revenue is generated in India; USD 0.143 billion in 2025, reaching USD 0.306 billion in 2034, and 26% of Asia Pacific.

4% of global revenue is generated in Australia; USD 0.066 billion in 2025, reaching USD 0.12 billion in 2034, and 12% of Asia Pacific.

In Latin America, 16.1% of global revenue puts 2025 at USD 0.266 billion with USD 0.545 billion projected for 2034. It is a mid-sized region on this axis, fourth by revenue throughout the period.

Its share rises to 18% over the forecast period, at a pace above the 7.03% global rate, which is what makes this region worth reading separately rather than scaling from the total.

Injection leads here as it does globally, at 46.18% of 2025 revenue, and Powder again grows fastest at 8.26%. The full report breaks Latin America out along every axis and by country.

USD 0.128 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 0.251 billion by 2034. 48.1% of the region in the base year makes it the largest market here without making it the region. Set against USD 0.266 billion and USD 0.545 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Brazil buys along the same lines as the market globally; Injection first at 46.18% of 2025 revenue and 43% in 2034, Powder fastest at 8.26% on a share moving from 29.82% to 33%. Since 48.1% of Latin America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Revenue by type for Brazil is reported separately in the full report.

In Brazil, ivermectin for human use is regulated by the Agência Nacional de Vigilância Sanitária, which requires a sanitary registration before a product can be marketed, along with conformity to Brazilian Good Manufacturing Practice standards and approved package labeling and patient leaflet content. Veterinary ivermectin formulations instead fall under the authority of the Ministério da Agricultura, Pecuária e Abastecimento, which maintains a separate registration and inspection regime for animal health products, including residue and withdrawal-period controls relevant to livestock use. Suppliers serving both segments must therefore pursue distinct approval pathways, and any promotional or labeling claim must remain within the scope of the specific registration granted for that formulation.

The suppliers tracked in this study (Hero Pharmaceutical, MERCK, HuBei YuanCheng SaiChuang, ENN, LAND, Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health, Virbac, Ceva Sante Animale, Huvepharma, Norbrook Laboratories and Cipla Limited) compete in Brazil across the type lines above. The commercially relevant division is 46.18% of 2025 revenue in Injection, where the volume is, against 8.26% growth in Powder, where share moves.

Argentina is sized at USD 0.059 billion in 2025, rising to USD 0.114 billion by 2034; 3.6% of global revenue and 22.2% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

In Middle East and Africa, 10.7% of global revenue puts 2025 at USD 0.177 billion rising to USD 0.364 billion in 2034. Among the five regions it ranks fifth by revenue in both years.

Share climbs to 12% by 2034, because it outgrows the market's 7.03%; the revenue added here is disproportionate to where the region started.

Within the region the type split tracks the global one; 46.18% of 2025 revenue in Injection, fastest growth of 8.26% in Powder. Per-axis and per-country detail for Middle East and Africa sits in the full report.

South Africa is the largest market within Middle East and Africa, generating USD 0.057 billion in 2025 and projected to reach USD 0.109 billion by 2034. At 32.2% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Set against USD 0.177 billion and USD 0.364 billion for the region, it is why this market rather than a smaller one is the one reported in full.

South Africa buys along the same lines as the market globally; Injection first at 46.18% of 2025 revenue and 43% in 2034, Powder fastest at 8.26% on a share moving from 29.82% to 33%. With 32.2% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-type revenue for South Africa appears on its own in the full report.

In South Africa, ivermectin for human use is regulated by the South African Health Products Regulatory Authority under the Medicines and Related Substances Act, which requires product registration confirming quality, safety, and efficacy before marketing, along with adherence to approved labeling and package insert requirements and to Good Manufacturing Practice standards. Ivermectin formulations intended for animal health, including agricultural and stock remedies, instead fall under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies framework administered through the Department of Agriculture, which sets its own registration and labeling conformity requirements distinct from the human medicines route. Suppliers must align each formulation with the correct regulatory pathway rather than relying on a single national approval.

Competition in South Africa runs between the suppliers this study tracks: Hero Pharmaceutical, MERCK, HuBei YuanCheng SaiChuang, ENN, LAND, Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health, Virbac, Ceva Sante Animale, Huvepharma, Norbrook Laboratories and Cipla Limited. Volume sits in Injection at 46.18% of 2025 revenue; movement sits in Powder at 8.26% growth.

Within Middle East and Africa, Saudi Arabia accounts for 19.8% of regional revenue and 2.1% of the global total, worth USD 0.035 billion in 2025 and USD 0.069 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, end use, distribution channel, product form, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.